Atraverse Medical Secures FDA Clearance for HOTWIRE Radiofrequency Guidewire and Raises $12.5 Million in Seed Funding

Recently, Atraverse Medical, a San Diego-based medical device company, announced the FDA clearance of its HOTWIRE radiofrequency (RF) guidewire. This innovative device enables zero exchange left-heart access while also serving as a rail for catheter-based therapy systems. The company also revealed that its seed round was oversubscribed, raising $12.5 million in funding.

These milestones represent a significant advancement in commercializing Atraverse Medical’s leading left-heart access technology. The funding includes contributions from prominent physicians, venture investors, and successful entrepreneurs in the medtech industry. This financial support will accelerate the company’s research and development efforts as well as its early commercialization initiatives.

Dr. Devi Nair, Director of Cardiac Electrophysiology and Research at St. Bernard’s Medical Center, expressed excitement about the impactful changes the HOTWIRE can bring to left-heart therapies. Meanwhile, Dr. Steven Mickelsen, Co-Founder of Atraverse and a cardiac electrophysiology physician at Scripps Hospital in Jolla, CA, highlighted the importance of FDA clearance for the HOTWIRE in advancing medical innovation and improving procedures requiring transseptal access.

According to John Slump, CEO/President and Co-Founder of Atraverse Medical, achieving FDA clearance and completing the seed round positions them for success in revolutionizing left-heart access technology.

The HOTWIRE system developed by Atraverse Co-Founders Dr. Mickelsen and Eric Sauter signifies a new approach to left-heart access with its universal sheath compatibility and optimized RF technology aiming to enhance patient outcomes and streamline procedural workflows.

Overall, these achievements have paved the way for Atraverse Medical to continue leading innovation in the field of left-heart access technology while positively impacting patient care outcomes.